Trial Profile
A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous(IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Burfiralimab (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- Sponsors ImmuneMed
- 14 Feb 2024 Status changed from recruiting to discontinued.
- 24 Aug 2021 Planned End Date changed from 1 Jul 2021 to 30 Dec 2021.
- 24 Aug 2021 Planned primary completion date changed from 1 Jun 2021 to 30 Nov 2021.